Evidence map›Paper›PMID 32274914›Full record

ReviewMinerva pediatrica2020

Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding.

Julia G Halas, Adda Grimberg

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Minerva pediatrica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Correlates of youth involvement in decision making about growth hormone treatment.Families, systems & health : the journal of collaborative family healthcare · 2025
    Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Current understanding and perspectives on growth and long-acting GH therapy in Japan.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Growth Hormone Treatment for Non-GHD Disorders: Excitement Tempered by Biology.The Journal of clinical endocrinology and metabolism · 2024
    Review
  17. Youth and Parent Perceptions of Youth Decision-Making Roles Regarding Evaluation for Short Stature.Children's health care : journal of the Association for the Care of Children's Health · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Julia G HalasCollege of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Adda GrimbergDivision of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA - Grimberg@email.chop.edu.
Children's Hospital of Philadelphia · USUniversity of the Sciences · US

Funding

A new paradigm of short stature: Incorporating parent and youth characteristics into understanding GH-related decision making and trajectories of quality of life and self-esteemR01HD097129 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI GRIMBERG, ADDA, MILLER, VICTORIA ALLISON · 2019 to 2023
$2.4M
NICHD NIH HHS R01 HD097129
6 · The paper itself

Abstract

Worrisome growth can be a sign of underlying pathology but usually reflects healthy variation. It is often recognized through short stature, which is defined by arbitrarily separating height, a physical trait on a continuum, into "normal" and "abnormal." In some cases of worrisome growth, recombinant human growth hormone (rhGH) treatment is indicated to hasten growth/increase height. This review addresses the two most frequently treated indications for rhGH, growth hormone deficiency (GHD) and idiopathic short stature (ISS). A review of worrisome growth itself, of the history of GH treatment, of the blurry line between partial GHD and ISS, of the GH stakeholders, and of the outside pressures involved in these cases demonstrates the ambiguous platform upon which treatment decisions are made. The rhGH treatment decision process can be examined further by considering the three most impactful factors on parental height-related medical decision-making: treatment characteristics, child health, and psychosocial function. While it is important to note that treatment for classical GHD is uncontroversial and supported, treatment decisions for partial GHD and ISS are more complicated and require careful evaluation of both patient needs and the supporting evidence. As the rhGH community grows, physicians, parents, and patients are encouraged to engage in a shared decision-making process to navigate the many challenges facing the GH field. Although this review addresses GHD and ISS specifically, the issues discussed are often applicable to pediatrics as a whole.

Indexed as

Body HeightChildGrowth DisordersHuman Growth HormoneHumansRecombinant ProteinsHuman Growth HormoneRecombinant Proteins

Identifiers

PMID32274914
PMCPMC7490116
OpenAlexW3015588436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.